secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silence Therapeutics plc (SLN)
CIK:        0001479615
Form:       8-K/A
Filed at:   2025-12-22T23:59:59+00:00
Accession:  0001193125-25-328684
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Silence Therapeutics discloses interim CEO pay and new director committee roles
-------------------------------------------------------------------------------

- Interim CEO Iain Ross receives £25,000/month cash for six months, then month-to-month, plus 900,000 option shares vesting over 12 months.
- New director James Ede-Golightly appointed to Remuneration, Audit & Risk, and Nominations Committees; granted 90,000 option shares vesting over 12 months.
- Ross is also eligible for a discretionary cash bonus as determined by the Remuneration Committee.
- Both option grants are under the company's 2023 Equity Incentive Plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479615/000119312525328684/0001193125-25-328684-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479615/000119312525328684/sln-20251214.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-328684

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer